TransCode Therapeutics, Inc., (RNAZ) News
Filter RNAZ News Items
RNAZ News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest RNAZ News From Around the Web
Below are the latest news stories about Transcode Therapeutics Inc that investors may wish to consider to help them evaluate RNAZ as an investment opportunity.
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent PortfolioBOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced that it has filed an International PCT Application (PCT/US21/65580) entitled TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY (the ‘580 application). The ‘580 application, expected to publish in June 2022, represents an extension of TransCode’s use of its patented RNA therapeutic platform to include using patter |
CORRECTION --TransCode TherapeuticsBOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE" earlier today by TransCode Therapeutics, Inc. (Nasdaq: RNAZ), please note that in the headline, the date of the conference should be 2022, not 2020 as previously stated. The corrected release follows: TransCode Therapeutics to Present at 2022 BIO CEO & INVESTOR CONFERENCE TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will |
TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCEBOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the 2022 BIO CEO & Investor Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes has the potential to significantly advance the treatment of cancer, including the company’s lead therapeutic candidate designed to treat metastatic disease. The Company is planning to file an explo |
TransCode Therapeutics To Participate at H.C. Wainwright BioConnect ConferenceBOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer. The Company plans to advance its lead therapeutic candidate, designed to treat metastatic disease, into its First in Human clini |
TransCode Therapeutics To Participate at MedInvest Oncology Investor ConferenceBOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the MedInvest Oncology Investor Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company’s lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its F |
Companies Like TransCode Therapeutics (NASDAQ:RNAZ) Are In A Position To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial ResultsBOSTON, November 15, 2021--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today reported recent business progress and third quarter 2021 financial results. |
TransCode Therapeutics Announces Participation in the Q4 Virtual Investor SummitBoston, Massachusetts--(Newsfile Corp. - November 9, 2021) - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced that it will be attending and presenting at the Q4 Virtual Investor Summit. TransCode's Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company's lead therapeutic candidate treating metastatic disease which it is advancing into the clinic wit |
TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology OfficerBOSTON, September 30, 2021--TransCode Therapeutics, Inc. (TransCode) (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today announced that Zdravka Medarova, Ph.D., has been appointed as the company’s Chief Technology Officer effective October 1, 2021. Dr. Medarova is a scientific co-founder of TransCode and has served as a member of TransCode’s advisory board since its fou |
Why Are TransCode Therapeutics Shares Shooting Higher On Thursday?TransCode Therapeutics Inc (NASDAQ: RNAZ) is trading higher after preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. Related: TransCode Therapeutics Secures NIH Funding To Support Its Lead Program Development. The preclinical study developed a radio-labeled derivative of TTX-MC138 tagged with Cu-64 for highly sensitive and specific quantitative determination of its pharmacokinetics, biodistribution, and observation, delivered to metastases via |